|
1
|
Agema BC, Koolen SL, de With M, van Doorn N, Heersche N, Oomen-de Hoop E, Visser S, Aerts JG, Bins S, van Schaik RH, Mathijssen RH. Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients. Genes (Basel) 2020; 11:genes11040358. [PMID: 32230800 PMCID: PMC7230333 DOI: 10.3390/genes11040358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 03/25/2020] [Accepted: 03/25/2020] [Indexed: 11/22/2022] Open
Abstract
Cisplatin is a chemotherapeutic agent widely used for multiple indications. Unfortunately, in a substantial set of patients treated with cisplatin, dose-limiting acute kidney injury (AKI) occurs. Here, we assessed the association of 3 catechol-O-methyltransferase (COMT) single nucleotide polymorphisms (SNPs) with increased cisplatin-induced nephrotoxicity. In total, 551 patients were genotyped for the 1947 G>A (Val158Met, rs4680), c.615 + 310 C>T (rs4646316), and c.616–367 C>T (rs9332377) polymorphisms. Associations between these variants and AKI grade ≥3 were studied. The presence of a homozygous variant of c.616-367C>T was associated with a decreased occurrence of AKI grade 3 toxicity (p = 0.014, odds ratio (OR) 0.201, 95% confidence interval (CI) (0.047–0.861)). However, we could not exclude the role of dehydration as a potential cause of AKI in 25 of the 27 patients with AKI grade 3, which potentially affected the results substantially. As a result of the low incidence of AKI grade 3 in this dataset, the lack of patients with a COMT variant, and the high number of patients with dehydration, the association between COMT variants and AKI does not seem clinically relevant.
Collapse
Affiliation(s)
- Bram C. Agema
- Department of Clinical Chemistry, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; (M.d.W.)
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands (N.v.D.); (N.H.); (E.O.-d.H.); (S.B.)
- Correspondence:
| | - Stijn L.W. Koolen
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands (N.v.D.); (N.H.); (E.O.-d.H.); (S.B.)
- Department of Clinical Pharmacy, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Mirjam de With
- Department of Clinical Chemistry, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; (M.d.W.)
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands (N.v.D.); (N.H.); (E.O.-d.H.); (S.B.)
| | - Nadia van Doorn
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands (N.v.D.); (N.H.); (E.O.-d.H.); (S.B.)
| | - Niels Heersche
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands (N.v.D.); (N.H.); (E.O.-d.H.); (S.B.)
| | - Esther Oomen-de Hoop
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands (N.v.D.); (N.H.); (E.O.-d.H.); (S.B.)
| | - Sabine Visser
- Department of Pulmonology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; (S.V.)
- Department of Pulmonology, Amphia Hospital, 4818 CK Breda, The Netherlands
| | - Joachim G.J.V. Aerts
- Department of Pulmonology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; (S.V.)
- Department of Pulmonology, Amphia Hospital, 4818 CK Breda, The Netherlands
| | - Sander Bins
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands (N.v.D.); (N.H.); (E.O.-d.H.); (S.B.)
| | - Ron H.N. van Schaik
- Department of Clinical Chemistry, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; (M.d.W.)
| | - Ron H.J. Mathijssen
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands (N.v.D.); (N.H.); (E.O.-d.H.); (S.B.)
| |
Collapse
|
|
2
|
Rehman FU, Jiang H, Selke M, Wang X. Mammalian cells: a unique scaffold forin situbiosynthesis of metallic nanomaterials and biomedical applications. J Mater Chem B 2018; 6:6501-6514. [DOI: 10.1039/c8tb01955j] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Nanoscale materials biosynthesis by using mammalian scaffold is green and highly biocompatible.
Collapse
Affiliation(s)
- Fawad Ur Rehman
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University
- Nanjing 210096
- People's Republic of China
- International Joint Center for Biomedical Innovation, Henan University
- Kaifeng
| | - Hui Jiang
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University
- Nanjing 210096
- People's Republic of China
| | - Matthias Selke
- Department of Chemistry and Biochemistry, California State University
- Los Angeles
- USA
| | - Xuemei Wang
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University
- Nanjing 210096
- People's Republic of China
| |
Collapse
|
|
3
|
de Jong C, Sanders S, Creemers GJ, Burylo AM, Taks M, Schellens JHM, Deenen MJ. Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman. Br J Clin Pharmacol 2017; 83:2120-2122. [PMID: 28560854 DOI: 10.1111/bcp.13309] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 04/03/2017] [Accepted: 04/11/2017] [Indexed: 11/29/2022] Open
Abstract
In this report we describe a young patient diagnosed with bulky FIGO stage IIIb squamous cell cervix carcinoma with severe and irreversible nephropathy after three weekly low-doses of cisplatin. Besides several known risk factors such as hypomagnesemia and hypoalbuminemia, the patient also proved to be homozygously polymorphic for two polymorphisms within the COMT gene (c.615 + 310C>T and c.616-367C>T). As COMT polymorphism has been associated with cisplatin-induced ototoxicity, its effect on nephrotoxicity of cisplatin should be the subject of further investigation.
Collapse
Affiliation(s)
- Corine de Jong
- Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, The Netherlands
| | - Stefan Sanders
- Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, The Netherlands
| | - Geert-Jan Creemers
- Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands
| | - Artur M Burylo
- Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Margot Taks
- Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, The Netherlands
| | - Jan H M Schellens
- Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.,Faculty of Science, Utrecht Institute of Pharmaceutical Sciences (UIPS), Division of Clinical Pharmacology and Pharmaco-epidemiology, Utrecht University, Utrecht, The Netherlands
| | - Maarten J Deenen
- Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, The Netherlands.,Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|